<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="of HIV infection: Raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), and" exact="bictegravir" post="(BIC). RAL was the first INSTI drug approved for"/>
 <result pre="clinical trial showed that a long-acting regimen of CAB and" exact="rilpivirine" post="(RPV) is noninferior for HIV maintenance therapy compared to"/>
 <result pre="(RPV) is noninferior for HIV maintenance therapy compared to DTG," exact="abacavir" post="(ABC), and lamivudine (3TC) in naÃ¯ve patients. However, 3"/>
 <result pre="for HIV maintenance therapy compared to DTG, abacavir (ABC), and" exact="lamivudine" post="(3TC) in naÃ¯ve patients. However, 3 participants experienced virological"/>
 <result pre="antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and" exact="bictegravir" post="in HIV-1 non-B subtypesAIDS20173246947610.1097/QAD.000000000000172629239896 41.FoleyB.LeitnerT.ParaskevisD.PeetersM.Primate immunodeficiency virus classification and"/>
</results>
